Clinical trial
Feasibility and Phase 2a Study of Relatlimab and Nivolumab (Opdualag™) in Adolescent and Young Adult Patients Newly Diagnosed With Replication Repair Deficient High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG)
NCT07644312 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility and Phase 2a Study of Relatlimab and Nivolumab (Opdualag™) in Adolescent and Young Adult Patients Newly Diagnosed With Replication Repair Deficient High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG)
- Lead sponsor
- Nationwide Children's Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 1, 2027
- Completion date
- March 1, 2038
- Enrollment
- 12 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse intrinsic pontine glioma, high grade glioma, replication repair deficient, who grade 3 glioma, who grade 4 glioma